| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
510,820,000 |
| Market
Cap: |
20.91(B) |
| Last
Volume: |
2,161,941 |
Avg
Vol: |
3,675,652 |
| 52
Week Range: |
$31.71 - $49.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 716 |
| Guru Rank Value : 1.5 |
| Guru Occurances : 4 |
|
|
|
|
|
| |
|
Company Profile Baxter International, through its subsidiaries, provides a portfolio of healthcare products, including acute and chronic dialysis therapies; sterile intravenous solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and patients at home under physician supervision. Co. manages its business based on the following geographic segments: Americas (North and South America), Europe, Middle East and Africa and Asia-Pacific.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
64,488 |
64,488 |
64,488 |
131,708 |
| Total Sell Value |
$2,618,858 |
$2,618,858 |
$2,618,858 |
$5,579,361 |
| Total People Sold |
1 |
1 |
1 |
3 |
| Total Sell Transactions |
1 |
1 |
1 |
4 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Karp Caroline |
CVP, Controller |
• – – |
2017-03-06 |
4 |
D |
$50.68 |
$5,220 |
D/D |
(103) |
12,384 |
|
- |
|
| Accogli Giuseppe |
CVP, Renal |
• – – |
2017-03-06 |
4 |
D |
$50.68 |
$5,676 |
D/D |
(112) |
22,209 |
|
- |
|
| Saccaro James |
CVP and CFO |
• – – |
2017-03-03 |
4 |
D |
$50.91 |
$134,046 |
D/D |
(2,633) |
49,325 |
|
- |
|
| Schabacker Marcus |
CVP, Chief Scientific Officer |
• – – |
2017-03-03 |
4 |
D |
$50.91 |
$74,023 |
D/D |
(1,454) |
35,889 |
|
- |
|
| Accogli Giuseppe |
CVP, Renal |
• – – |
2017-03-03 |
4 |
D |
$50.91 |
$41,695 |
D/D |
(819) |
22,322 |
|
- |
|
| Karp Caroline |
CVP, Controller |
• – – |
2017-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,508 |
12,885 |
|
- |
|
| Loeb Daniel S |
See Remarks |
– • – |
2017-02-28 |
4 |
S |
$50.35 |
$297,153,968 |
I/I |
(5,901,767) |
46,001,790 |
|
- |
|
| Hellman Peter S |
Director |
– • – |
2017-02-22 |
4 |
S |
$49.81 |
$213,187 |
D/D |
(4,280) |
20,140 |
|
- |
|
| Hellman Peter S |
Director |
– • – |
2017-02-22 |
4 |
OE |
$30.73 |
$131,524 |
D/D |
4,280 |
24,420 |
|
- |
|
| Scharf David P. |
CVP and General Counsel |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
24,902 |
109,789 |
|
- |
|
| Scharf David P. |
CVP and General Counsel |
• – – |
2017-02-21 |
4 |
D |
$49.96 |
$509,692 |
D/D |
(10,202) |
102,087 |
|
- |
|
| Saccaro James |
CVP and CFO |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
9,905 |
51,958 |
|
- |
|
| Schabacker Marcus |
CVP, Chief Scientific Officer |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
8,454 |
37,190 |
|
- |
|
| Schabacker Marcus |
CVP, Chief Scientific Officer |
• – – |
2017-02-21 |
4 |
D |
$49.96 |
$68,695 |
D/D |
(1,375) |
31,909 |
|
- |
|
| Almeida Jose E |
Chairman of the Board and CEO |
• • – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
42,635 |
54,326 |
|
- |
|
| Vibert Paul |
CVP, International |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
7,698 |
52,914 |
|
- |
|
| Vibert Paul |
CVP, International |
• – – |
2017-02-21 |
4 |
D |
$49.96 |
$58,403 |
D/D |
(1,169) |
47,633 |
|
- |
|
| Mason Jeanne K |
CVP, Human Resources |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
17,788 |
106,507 |
|
- |
|
| Mason Jeanne K |
CVP, Human Resources |
• – – |
2017-02-21 |
4 |
D |
$49.96 |
$322,342 |
D/D |
(6,452) |
101,005 |
|
- |
|
| Eyre Brik V |
CVP, Hospital Products |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
12,344 |
47,653 |
|
- |
|
| Eyre Brik V |
CVP, Hospital Products |
• – – |
2017-02-21 |
4 |
D |
$49.96 |
$88,529 |
D/D |
(1,772) |
39,401 |
|
- |
|
| Accogli Giuseppe |
CVP, Renal |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,271 |
22,996 |
|
- |
|
| Accogli Giuseppe |
CVP, Renal |
• – – |
2017-02-21 |
4 |
D |
$49.96 |
$26,779 |
D/D |
(536) |
21,966 |
|
- |
|
| Forsyth John D |
Director |
– • – |
2017-02-08 |
4 |
S |
$48.35 |
$206,938 |
D/D |
(4,280) |
27,058 |
|
- |
|
| Forsyth John D |
Director |
– • – |
2017-02-08 |
4 |
OE |
$30.73 |
$131,524 |
D/D |
4,280 |
31,338 |
|
- |
|
1255 Records found
|
|
Page 19 of 51 |
|
|
0.09 (0.22%) 
